JP2018531967A5 - - Google Patents

Download PDF

Info

Publication number
JP2018531967A5
JP2018531967A5 JP2018521655A JP2018521655A JP2018531967A5 JP 2018531967 A5 JP2018531967 A5 JP 2018531967A5 JP 2018521655 A JP2018521655 A JP 2018521655A JP 2018521655 A JP2018521655 A JP 2018521655A JP 2018531967 A5 JP2018531967 A5 JP 2018531967A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
disease
compound
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018521655A
Other languages
English (en)
Other versions
JP2018531967A (ja
JP6789288B2 (ja
Filing date
Publication date
Priority claimed from GBGB1518950.9A external-priority patent/GB201518950D0/en
Application filed filed Critical
Publication of JP2018531967A publication Critical patent/JP2018531967A/ja
Publication of JP2018531967A5 publication Critical patent/JP2018531967A5/ja
Application granted granted Critical
Publication of JP6789288B2 publication Critical patent/JP6789288B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (12)

  1. Figure 2018531967
    である化合物。
  2. 結晶形態である、請求項1に記載の化合物。
  3. 治療上有効な量の請求項1または請求項2に記載の化合物と、薬学上許容可能な賦形剤とを含んでなる、医薬組成物。
  4. 経口投与のための、請求項3に記載の医薬組成物。
  5. 抗SAP抗体の1以上の投与形と、請求項1〜4のいずれか一項に記載の化合物または医薬組成物の1以上の投与形とを含んでなる、パーツのキット。
  6. 請求項1または2に記載の化合物を含んでなる、医薬組成物
  7. SAP枯渇において使用するための、請求項に記載の医薬組成物。
  8. SAP枯渇が有益である疾患または障害の処置において使用するための、請求項に記載の医薬組成物。
  9. 前記疾患または障害が、アミロイドーシス、アルツハイマー病、2型糖尿病および骨関節炎からなる群から選択される、請求項に記載の医薬組成物
  10. 前記疾患または障害がアミロイドーシスである、請求項に記載の医薬組成物
  11. 前記疾患または障害が全身性アミロイドーシスである、請求項に記載の医薬組成物
  12. 抗SAP抗体と組み合わせて用いるための、請求項10または11に記載の医薬組成物
JP2018521655A 2015-10-27 2016-10-25 Sap枯渇剤としてのd−プロリン誘導体 Active JP6789288B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1518950.9 2015-10-27
GBGB1518950.9A GB201518950D0 (en) 2015-10-27 2015-10-27 Compound
PCT/EP2016/075632 WO2017072099A1 (en) 2015-10-27 2016-10-25 D-proline derivatives as sap depleting agent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020182835A Division JP7053762B2 (ja) 2015-10-27 2020-10-30 Sap枯渇剤としてのd-プロリン誘導体

Publications (3)

Publication Number Publication Date
JP2018531967A JP2018531967A (ja) 2018-11-01
JP2018531967A5 true JP2018531967A5 (ja) 2019-12-05
JP6789288B2 JP6789288B2 (ja) 2020-11-25

Family

ID=55130261

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018521655A Active JP6789288B2 (ja) 2015-10-27 2016-10-25 Sap枯渇剤としてのd−プロリン誘導体
JP2020182835A Active JP7053762B2 (ja) 2015-10-27 2020-10-30 Sap枯渇剤としてのd-プロリン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020182835A Active JP7053762B2 (ja) 2015-10-27 2020-10-30 Sap枯渇剤としてのd-プロリン誘導体

Country Status (12)

Country Link
US (1) US10328052B2 (ja)
EP (1) EP3368532B1 (ja)
JP (2) JP6789288B2 (ja)
KR (1) KR20180067559A (ja)
CN (1) CN108368095B (ja)
AU (1) AU2016345462A1 (ja)
BR (1) BR112018008582A2 (ja)
CA (1) CA3002710A1 (ja)
ES (1) ES2781550T3 (ja)
GB (1) GB201518950D0 (ja)
RU (1) RU2018119120A (ja)
WO (1) WO2017072099A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202111866D0 (en) 2021-08-18 2021-09-29 Ucl Business Plc Prodrugs for use in the treatment of tissue damage

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859031A (en) * 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
ATE224366T1 (de) * 1997-10-31 2002-10-15 Hoffmann La Roche D-prolinderivate
US6903129B2 (en) 2001-12-14 2005-06-07 Hoffman-La Roche Inc. D-proline prodrugs
US7265140B2 (en) 2003-09-23 2007-09-04 Pfizer Inc Acyloxymethylcarbamate prodrugs of oxazolidinones
US8236792B2 (en) * 2008-05-23 2012-08-07 Janssen Pharmaceutica Nv Substituted pyrrolidine amides as modulators of the histamine H3 receptor
GB201407506D0 (en) 2014-04-29 2014-06-11 Glaxosmithkline Ip Dev Ltd Novel compound
US9737505B2 (en) 2014-04-29 2017-08-22 Glaxosmithkline Intellectual Property Development Limited Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline

Similar Documents

Publication Publication Date Title
JP2017509667A5 (ja)
JP2016518337A5 (ja)
JP2014507446A5 (ja)
JP2017075173A5 (ja)
JP2013525444A5 (ja)
JP2017149726A5 (ja)
JP2017048208A5 (ja)
JP2016185995A5 (ja)
JP2019516735A5 (ja)
JP2013505205A5 (ja)
JP2015187156A5 (ja)
JP2016515522A5 (ja)
JP2015501783A5 (ja)
JP2015057451A5 (ja)
JP2015212268A5 (ja)
RU2017105353A (ru) Соединения
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
JP2015110588A5 (ja)
JP2019529514A5 (ja)
JP2012193216A5 (ja)
JP2015530399A5 (ja)
JP2016510326A5 (ja)
EA201791067A1 (ru) Способы лечения субъектов с синдромом прадера-вилли или синдромом смита-магениса
CY1124115T1 (el) Η χρηση τριβενζοϊκου γλυκερυλιου που περιεχει συνθεση σε νευροεκφυλιστικες διαταραχες
JP2016512817A5 (ja)